A Double Blind, Placebo Controlled Study of the Effect of 330 mg QD of TRO19622 in the Treatment of Chemotherapy Induced Peripheral Neuropathy.

Trial Profile

A Double Blind, Placebo Controlled Study of the Effect of 330 mg QD of TRO19622 in the Treatment of Chemotherapy Induced Peripheral Neuropathy.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2016

At a glance

  • Drugs Olesoxime (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Acronyms CIPN
  • Sponsors Roche; Trophos
  • Most Recent Events

    • 27 Dec 2012 Status changed from unconfirmed to completed as reported by ClinicalTrials.gov.
    • 12 Jul 2012 Status changed from recruiting to unconfirmed.
    • 17 Apr 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top